Production (Stage)
D
Apogee Therapeutics, Inc. APGE
$39.48 -$0.88-2.18% NASDAQ
Recommendation
Prev Close
$39.48
Volume
405,972
Avg Vol (90D)
651,817
Market Cap
$2.30B
Dividend & Yield
--
52-Week Range
$26.20 - $63.50
P/E (TTM)
--
EPS (TTM)
-$3.59
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Neo Ivy Capital Management Makes New Investment in Apogee Therapeutics, Inc. (NASDAQ:APGE)
5/24/2025 - Ticker Report
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
5/21/2025 - Zacks Investment Research
Soleus Capital Management L.P. Invests $3.17 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE)
5/21/2025 - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Acquired by Woodline Partners LP
5/20/2025 - Ticker Report
Point72 Asset Management L.P. Lowers Stake in Apogee Therapeutics, Inc. (NASDAQ:APGE)
5/20/2025 - MarketBeat
Soleus Capital Management L.P. Invests $3.17 Million in Apogee Therapeutics, Inc. (NASDAQ:APGE)
5/19/2025 - Ticker Report
Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Bought by Paradigm Biocapital Advisors LP
5/16/2025 - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for APGE
5/16/2025 - MarketBeat
Janus Henderson Group PLC Buys 665,543 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)
5/16/2025 - MarketBeat
Apogee Therapeutics, Inc. (NASDAQ:APGE) Holdings Cut by Comerica Bank
5/15/2025 - MarketBeat
Apogee Therapeutics (NASDAQ:APGE) Issues Quarterly Earnings Results, Beats Expectations By $0.24 EPS
5/14/2025 - MarketBeat
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4R? Class
5/12/2025 - Seeking Alpha - Long Ideas
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4R? Class
5/12/2025 - SeekingAlpha
Apogee Therapeutics reports positive results from asthma treatment trial
5/12/2025 - Seeking Alpha - Healthcare
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 ...
5/12/2025 - GuruFocus
Apogee Therapeutics Inc (APGE) Announces Significant Pipeline Progress and Financial Results ...
5/12/2025 - GuruFocus
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 ...
5/12/2025 - GuruFocus
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its ...
5/12/2025 - GuruFocus
Apogee Therapeutics (APGE) Reports Promising Phase 1b Trial Results for Asthma Drug APGE ...
5/12/2025 - GuruFocus
Apogee Therapeutics Reports Positive Phase 1b Trial Results
5/12/2025 - TipRanks Financial Blog
Apogee Therapeutics reports data from Phase 1b trial of APG808
5/12/2025 - The Fly
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its ...
5/12/2025 - GuruFocus
Apogee Therapeutics Inc (APGE) Announces Promising Phase 1b Trial Results for APG808 in Asthma ...
5/12/2025 - GuruFocus
Apogee Therapeutics reports Q1 net loss ($55.3M) vs. ($32.1M) last year
5/12/2025 - The Fly
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
5/12/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$241.42M
EBIT (TTM)
-$241.79M
Net Income (TTM)
-$205.39M
Balance Sheet
Total Assets (Q)
$714.16M
Total Debt (Q)
$11.82M
Total Liabilities (Q)
$40.80M
Book Value Per Share (Q)
$11.55
Cash Flow
Cash from Operations (TTM)
-$188.02M
Cash from Investing (TTM)
-$235.74M
Cash from Financing (TTM)
$45.21M
Net Change in Cash (TTM)
-$378.54M
Filings
Filing Date
Monday, May 12, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-2.85%
30-Day Total Return
24.15%
60-Day Total Return
25.57%
90-Day Total Return
-2.42%
Year to Date Total Return
-16.27%
1-Year Total Return
-17.80%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 08, 2025 - $26.20
52-week High
Nov 11, 2024 - $63.50
Valuation
Market Cap
$2.30B - Mid Cap
Enterprise Value
$1.63B
Price/Sales (TTM)
--
Price/Book (Q)
3.42
Dividends and Shares
Shares Outstanding
58.20M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.apogeetherapeutics.com
Phone Number
650 394 5230
Address
Building 17
Suite 102b - 221 Crescent Street
Waltham, MA 02453
Country
United States
Year Founded
2022
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed